Related Experiment Video

Updated: May 13, 2026

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

Therapeutic applications of PI3K inhibitors in cardiovascular diseases

Alessandra Ghigo1, Fulvio Morello, Alessia Perino

  • 1University of Torino, Molecular Biotechnology Center, Department of Molecular Biotechnology & Health Sciences, Via Nizza 52, 10126, Torino, Italy.

Future Medicinal Chemistry
|March 19, 2013
PubMed

Insights

Phosphoinositide 3-kinases (PI3Ks) are key in cardiovascular diseases. Inhibiting PI3Ks shows promise for treating hypertension, atherosclerosis, and heart failure in preclinical models.

Area of Science:

  • Cardiovascular Biology
  • Pharmacology
  • Enzymology

Background:

  • Phosphoinositide 3-kinases (PI3Ks) are crucial signaling enzymes activated in various cardiovascular diseases.
  • These enzymes are implicated in conditions including hypertension, atherosclerosis, thrombosis, and heart failure.
  • Genetic studies in animal models demonstrate that blocking PI3Ks can impact disease progression.

Purpose of the Study:

  • To review the rationale for targeting PI3K signaling in prevalent cardiovascular diseases.
  • To summarize preclinical data on the therapeutic effects of PI3K inhibitors.
  • To discuss the future implications for drug development and human therapy.

Main Methods:

  • Review of existing literature on PI3K signaling in cardiovascular diseases.
  • Analysis of preclinical studies investigating PI3K inhibitors.
  • Discussion of genetic modification studies in animal models.

Main Results:

  • PI3K inhibition demonstrates potential in preclinical models for cardiovascular conditions.
  • Therapeutic strategies targeting PI3Ks may reduce blood pressure and restrain atherosclerosis.
  • PI3K inhibitors show promise in stabilizing plaques, preventing remodeling, and preserving heart function.

Conclusions:

  • PI3K inhibition is a promising therapeutic strategy for cardiovascular diseases.
  • Further drug development and clinical trials are warranted based on preclinical evidence.
  • Targeting PI3Ks offers a potential new avenue for managing complex cardiovascular conditions.

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: